Following the latest results, Pro Medicus' 13 analysts are now forecasting revenues of AU$215.8m in 2025. This would be a decent 16% improvement in revenue compared to the last 12 months.

Pro Medicus’ strategy revolves around renewing existing contracts and winning new clients for its main product, Visage 7, while increasing its price point. The company won six out of six major ...

The Pro Medicus Limited (ASX: PME) share price is rising again on Thursday morning. In early trade, the health imaging technology company's shares are up 4% to an all-time high of $298.98.

Learn More Pro Medicus Limited (ASX: PME) shares were under pressure on Thursday. After initially charging to a record high, the health imaging technology company's shares ended the session 3% ...

What is the current share price of Pro Medicus Limited (PME)? Pro Medicus Limited's (PME) current share price is $253.25. This constitutes a price movement of 11.39% when compared to the share price 7 ...

Healthcare imaging software company Pro Medicus ((PME)) achieved record revenue and net profit in the first half of FY25, driven in part by nearly $500m in new Visage product suite contracts signed ...

Despite its sky-high valuation, Jun Bei Liu, co-founder and lead portfolio manager at the newly launched active manager TenCap, remains one of Pro Medicus' (ASX: PME) earliest and most vocal champions ...

Pro Medicus delivered solid 1H25 results, with revenue up 31% and net profit up 45%, but shares fell as valuation concerns outweighed the earnings beat PME hit a record high before reversing sharply, ...

In the case of healthcare imaging IT provider – Pro Medicus - there are three. Of course, the financials still matter. On that front, it’s hard to fault the recent results – many of which were records ...

At close: March 7 at 3:00:00 PM EST Loading Chart for PMCUF ...

CSL and Cochlear are two of Australia’s blue-chip healthcare stocks, stalwarts of many investors portfolios, whereas Pro Medicus is likely either a relatively new addition, or is on many investors’ ...